肝肺综合征与低1-磷酸鞘氨醇水平相关,且可被功能性激动剂芬戈莫德改善
研究比较44例肝肺综合征(HPS)肝硬化患者、89例无HPS肝硬化患者及25名健康对照的血浆1-磷酸鞘氨醇(S1P)、NO及炎症标志物,并在胆总管结扎(CBDL)小鼠模型中评估S1P与芬戈莫德的作用。HPS患者血浆S1P对数水平显著低于无HPS者,且重度肺内分流者更低;芬戈莫德改善CBDL模型氧合、炎症与生存。
要点
- HPS患者血浆S1P对数水平显著低于无HPS者(3.1±1.4 vs 4.6±0.2,p<0.001)。
- HPS患者血浆TNF-α与NO水平高于无HPS者,Th17与T调节细胞增加。
- CBDL小鼠模型中芬戈莫德改善氧合、减少炎症并提高生存(p=0.02)。
核心结论
- HPS患者血浆S1P水平低,重度肺内分流者更低,低S1P与严重肺血管分流相关,可作为HPS疾病严重程度的标志物。
- 在CBDL小鼠HPS模型中,芬戈莫德通过改善肺血管张力与氧合提高生存,作者提出其作为HPS潜在新疗法。
研究设计与样本
- 研究纳入44例伴HPS的肝硬化患者、89例不伴HPS的肝硬化患者和25名健康对照,检测血浆S1P、NO及全身炎症标志物。
- 采用胆总管结扎(CBDL)小鼠HPS模型,在给予S1P和芬戈莫德前后评估肺血管变化、动脉氧合、肝纤维化与炎症。
主要发现
- HPS患者血浆S1P对数水平显著低于无HPS者(3.1±1.4 vs 4.6±0.2;p<0.001),重度肺内分流者低于轻中度肺内分流者(p<0.001)。
- HPS患者血浆TNF-α(76.5 [30.3-91.6] vs 52.9 [25.2-82.8];p=0.02)和NO(152.9±41.2 vs 79.2±29.2;p=0.001)水平高于无HPS者。
- 观察到Th17(p<0.001)和T调节细胞(p<0.001)增加,后者与血浆S1P水平呈负相关。
- 在CBDL HPS模型中,芬戈莫德通过增加动脉血气交换、减少全身与肺部炎症来修复肺血管损伤,改善生存(p=0.02)。
- 与溶媒治疗相比,芬戈莫德降低门静脉压力(p<0.05)和肝纤维化、改善肝细胞增殖,诱导肝星状细胞凋亡并减少胶原形成。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS) is characterised by a defect in arterial oxygenation induced by pulmonary vascular dilatation in patients with liver disease. Fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, suppresses vasodilation by reducing nitric oxide (NO) production. We investigated the role of S1P in patients with HPS and the role of fingolimod as a therapeutic option in an experimental model of HPS. METHODS: Patients with cirrhosis with HPS (n = 44) and without HPS (n = 89) and 25 healthy controls were studied. Plasma levels of S1P, NO, and markers of systemic inflammation were studied. In a murine model of common bile duct ligation (CBDL), variations in pulmonary vasculature, arterial oxygenation, liver fibrosis, and inflammation were estimated before and after administration of S1P and fingolimod. RESULTS: Log of plasma S1P levels was significantly lower in patients with HPS than in those without HPS (3.1 ± 1.4 vs. 4.6 ± 0.2; p <0.001) and more so in severe intrapulmonary shunting than in mild and moderate intrapulmonary shunting (p <0.001). Plasma tumour necrosis factor-α (76.5 [30.3-91.6] vs. 52.9 [25.2-82.8]; p = 0.02) and NO (152.9 ± 41.2 vs. 79.2 ± 29.2; p = 0.001) levels were higher in patients with HPS than in those without HPS. An increase in Th17 (p <0.001) and T regulatory cells (p <0.001) was observed; the latter inversely correlated with plasma S1P levels. In the CBDL HPS model, fingolimod restored pulmonary vascular injury by increasing the arterial blood gas exchange and reducing systemic and pulmonary inflammation, resulting in improved survival (p = 0.02). Compared with vehicle treatment, fingolimod reduced portal pressure (p <0.05) and hepatic fibrosis and improved hepatocyte proliferation. It also induced apoptotic death in hepatic stellate cells and reduced collagen formation. CONCLUSIONS: Plasma S1P levels are low in patients with HPS and even more so in severe cases. Fingolimod, by improving pulmonary vascular tone and oxygenation, improves survival in a murine CBDL HPS model. IMPACT AND IMPLICATIONS: A low level of plasma sphingosine-1-phosphate (S1P) is associated with severe pulmonary vascular shunting, and hence, it can serve as a marker of disease severity in patients with hepatopulmonary syndrome (HPS). Fingolimod, a functional agonist of S1P, reduces hepatic inflammation, improves vascular tone, and thus retards the progression of fibrosis in a preclinical animal model of HPS. Fingolimod is being proposed as a potential novel therapy for management of patients with HPS.
引用
- Baweja S, Kumari A, Negi P, et al. Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. J Hepatol. 2023. PMID: 36996943. doi:10.1016/j.jhep.2023.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。